ROR1 CAR-T cells and ferroptosis inducers orchestrate tumor ferroptosis via PC-PUFA2 by Dan Li, Wenjie Zhang, Ruiheng Wang, Shufeng Xie, Yixin Wang, Wanxin Guo, Zixuan Huang, Chaoqun Lu, Liang Shan, Han Liu, Lifang Ma, Xumin Hou, Zhenshu Xu, Jiayi Wang

“…Emerging therapies, such as chimeric antigen receptor (CAR)-T cell therapy, have shown promise but face significant challenges in targeting solid tumors. …”
Get full text

Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin by Jichao Sun, Dinglan Wu, Liuhai Zheng, Huifang Wang, Jihao Zhou, Guangwei Shi, Jingbo Ma, Yuke Jiang, Zhiyu Dong, Jiexuan Li, Yuan-Qiao He, Chengchao Xu, Zhijie Li, Jigang Wang

“…Background Chimeric antigen receptor natural killer (CAR-NK) therapy holds great promise for treating hematologic tumors, but its efficacy in solid tumors is limited owing to the lack of suitable targets and poor infiltration of engineered NK cells. …”
Get full text

Development of chimeric Nanobody-Granzyme B functionalized ferritin nanoparticles for precise tumor therapy by Baijin Xia, Huolun Feng, Xinmiao Jiang, Jialing Guo, Keming Lin, Wenxing Zhang, Fan Xing, Lixue Cao, Yong Li, Hui Zhang, Xu Zhang, Wenyu Li, Fei Yu

“…The efficacy of traditional T-cell therapies, including chimeric antigen receptor (CAR) T cells, is often constrained by immunosuppressive factors and the tumor microenvironment. …”
Get full text

XCL1-secreting CEA CAR-T cells enhance endogenous CD8+ T cell responses to tumor neoantigens to confer a long-term antitumor immunity by Kun Chen, Fei Zhao, Hong Zhao, Dongmei Wang, Chunfeng Qu, Zhiyuan Wu, Feifei Wang, Xing-Ning Li, Ruochan Zhang, Chentong Xiao, Yuliang Ran

“…Background Therapeutic efficacy of carcinoembryonic antigen (CEA)-specific chimeric antigen receptor (CAR) T cells against colorectal cancer (CRC) remains limited due to the unique characteristics and distinct microenvironments of tumor tissues. …”
Get full text

Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells by Luciana Melo Garcia, Achintyan Gangadharan, Pinaki Banerjee, Ye Li, Andy G.X. Zeng, Hind Rafei, Paul Lin, Bijender Kumar, Sunil Acharya, May Daher, Luis Muniz-Feliciano, Gary M. Deyter, Gabriel Dominguez, Jeong Min Park, Francia Reyes Silva, Ana Karen Nunez Cortes, Rafet Basar, Nadima Uprety, Mayra Shanley, Mecit Kaplan, Enli Liu, Elizabeth J. Shpall, Katayoun Rezvani

“…Engineering NK cells to express a chimeric antigen receptor targeting the AML antigen CD38 (CAR38) could overcome the need for CD226 to establish strong immune synapses. …”
Get full text

Development and validation of predictive models of early immune effector cell–associated hematotoxicity by Emily C. Liang, Jennifer J. Huang, Andrew J. Portuguese, Valentín Ortiz-Maldonado, Aya Albittar, Natalie Wuliji, Ryan Basom, Yein Jeon, Qian Wu, Aiko Torkelson, Delaney Kirchmeier, Abigail Chutnik, Barbara Pender, Mohamed Sorror, Joshua A. Hill, Noam E. Kopmar, Rahul Banerjee, Andrew J. Cowan, Damian Green, Ajay K. Gopal, Christina Poh, Mazyar Shadman, Alexandre V. Hirayama, Brian G. Till, Erik L. Kimble, Lorenzo Iovino, Aude G. Chapuis, Folashade Otegbeye, Ryan D. Cassaday, Filippo Milano, Cameron J. Turtle, David G. Maloney, Jordan Gauthier

“…Abstract: Immune effector cell–associated hematotoxicity (ICAHT) is associated with morbidity and mortality after chimeric antigen receptor (CAR) T-cell therapy. To date, the factors associated with ICAHT are poorly characterized, and there is no validated predictive model of ICAHT as defined by current consensus criteria. …”
Get full text

Enhancement of anti‐sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2‐targeted CAR by Pui Yeng Lam, Natacha Omer, Josh K. M. Wong, Cui Tu, Louisa Alim, Gustavo R. Rossi, Maria Victorova, Hannah Tompkins, Cheng‐Yu Lin, Ahmed M. Mehdi, Amos Choo, Melissa R. Elliott, Elaina Coleborn, Jane Sun, Timothy Mercer, Orazio Vittorio, Lachlan J. Dobson, Alexander D. McLellan, Andrew Brooks, Zewen Kelvin Tuong, Seth W. Cheetham, Wayne Nicholls, Fernando Souza‐Fonseca‐Guimaraes

“…The advent of chimeric antigen receptor (CAR)‐based immunotherapies offers a promising avenue for novel treatments. …”
Get full text

Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study by Fiona Reid, Sophie Papa, John Maher, Jean-Pierre Jeannon, James Spicer, Victoria Gibson, Selvam Thavaraj, Michael Metoudi, Christopher Fisher, Nicholas Beckley-Hoelscher, Andrew Hope, Maria Elstad, Antonella Adami, Richard Beatson, Molly Sarah George, Daniela Achkova, Evangelia Williams, Sefina Arif, Abdel Douri, Marc Delord, Mike Lyne, Dharshene Shivapatham, Sakina Gooljar, Arindam Mitra, Linda Gomm, Cienne Morton, Rhonda Henley-Smith, Alice Santambrogio, Cynthia Andoniadou, Sarah Allen, Gary J R Cook, Ana C Parente-Pereira, David M Davies, Farzin Farzaneh, Anna Schurich, Teresa Guerrero-Urbano

“…To target upregulated ErbB dimer expression in this cancer, we developed an autologous CD28-based chimeric antigen receptor T-cell (CAR-T) approach named T4 immunotherapy. …”
Get full text

Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma by Inés Zugasti, Marta Tormo-Ratera, Aina Oliver-Caldés, Juan Carlos Soler-Perromat, Verónica González-Calle, David F. Moreno, Valentín Cabañas, Nieves López-Muñoz, Álvaro Bartolomé-Solanas, Marta Español-Rego, Juan Luis Reguera-Ortega, Laura Rosiñol, Lucía López-Corral, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, Rosa Maria Alvarez Perez, Sara Varea, Eulàlia Olesti, Adolfo Gomez-Grande, Laura Frutos, Pilar Tamayo, Manel Juan, José M. Moraleda, Álvaro Urbano-Ispizua, E. Azucena González-Navarro, Joaquín Martínez-López, Maria-Victoria Mateos, Xavier Tomás, Xavier Setoain, Carlos Fernández de Larrea

“…Abstract: Multiple myeloma (MM) remains incurable, with poor outcomes in heavily pretreated patients. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment; however, outcomes after such therapy in patients with soft-tissue plasmacytomas and other bone lesions remain poorly understood. …”
Get full text

Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review by Marco Ruella, Guido Ghilardi, Zainul S. Hasanali, Sandra P. Susanibar-Adaniya, Lena E. Winestone, Alfred L. Garfall

“…Chimeric antigen receptor T cell (CAR-T) therapies are now standard-of-care for several B-cell malignancies, and additional indications are being evaluated. …”
Get full text

Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies by Shangjun Sun, He Hao, Ge Yang, Yi Zhang, Yang Fu

“…T cells modified via chimeric antigen receptors (CARs) have emerged as a promising treatment modality. …”
Get full text

Loading of CAR‐T cells with magnetic nanoparticles for controlled targeting suppresses inflammatory cytokine release and switches tumor cell death mechanism by Felix Pfister, Lucas R. Carnell, Lisa Löffler, Philipp Boosz, Niels Schaft, Jan Dörrie, René Stein, Malte Lenz, Erdmann Spiecker, Christian M. Huber, Sami Haddadin, Carola Berking, Christoph Alexiou, Christina Janko

“…Abstract Therapies against hematological malignancies using chimeric antigen receptors (CAR)‐T cells have shown great potential; however, therapeutic success in solid tumors has been constrained due to limited tumor trafficking and infiltration, as well as the scarcity of cancer‐specific solid tumor antigens. …”
Get full text

mRNA vaccines as cancer therapies by Shaoxiong Huang, Haiying Que, Manni Wang, Xiawei Wei, Yanjie Yin

“…Derived from reported literature and data on clinicaltrials.gov, it examines studies on mRNA vaccines encoding tumor-specific antigens (TSAs), tumor-associated antigens (TAAs), immunomodulators, and chimeric antigen receptors (CARs) across various cancer types. …”
Get full text

CAR T cells for treating autoimmune diseases by Dimitrios Mougiakakos, Ulrike Koehl, Stephan Fricke, Ulrich Blache, Sandy Tretbar

“…In the wake of its success in cancer therapy, adoptive transfer of engineered T cells modified with chimeric antigen receptors (CAR) for target recognition could now become a therapeutic option for some autoimmune diseases. …”
Get full text

Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions by Ghaleb Elyamany, Eman Al Mussaed, Ali Matar Alzahrani

“…The introduction of genes encoding artificial receptors called chimeric antigen receptors (CARs) and CAR-modified T cells targeted to the B cell-specific CD19 antigen have demonstrated promising results in multiple early clinical trials. …”
Get full text

Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies by Sandro Matosevic

“…Alongside expressing chimeric antigen receptors to overcome immune escape by cancer cells, enhance their recognition, and mediate their killing, NK cells have been genetically modified to enhance their persistence in vivo by the expression of cytokines such as IL-15, avoid functional and metabolic tumor microenvironment suppression, or improve their homing ability, enabling enhanced targeting of solid tumors. …”
Get full text

Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice by Dai Fukumura, Rakesh K Jain, Jun Ren, Xinyue Dong, Zohreh Amoozgar, Somin Lee, Meenal Datta, Sylvie Roberge, Mark Duquette

“…Chimeric antigen receptor (CAR)-T cells have revolutionized the treatment of multiple types of hematological malignancies, but have shown limited efficacy in patients with glioblastoma (GBM) or other solid tumors. …”
Get full text

PSMA antibody, humanized PSMA.CAR10.3, or Cetuximab increases prostate cancer localization of NF-κB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macroph... by Mohammad A. Alzubi, Theresa Barberi, Alan D. Friedman

“…Directing p50-IMC to tumors using Fc receptor-bound antibodies (Abs) or surface chimeric antigen receptors (CARs) may increase tumor localization and subsequent phagocytosis of cancer cells by their mature myeloid progeny, potentiating anti-tumor T cell activation. …”
Get full text

CD94-driven in vitro expansion of highly functional adaptive NKG2C+ NKG2A- CD57+ NK cells from CMV+ healthy donors by Chiara Giordano, Simona Carlomagno, Simona Carlomagno, Michela Falco, Claudia Cantoni, Claudia Cantoni, Massimo Vitale, Ignazio Caruana, Johannes Dirks, Alberto Serio, Letizia Muccio, Giulia Bartalucci, Alessandra Bo, Franco Locatelli, Franco Locatelli, Cristina Bottino, Cristina Bottino, Simona Sivori, Simona Sivori, Mariella Della Chiesa, Mariella Della Chiesa

“…In light of these features, adaptive NK cells represent suitable candidate to design next-generation therapies, based on their enhanced effector function which could be further boosted by Chimeric Antigen Receptors-engineering, or the combination with cell engagers. …”
Get full text

CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses by Alice Bergamini, Barbara Camisa, Attilio Bondanza, Fabio Ciceri, Chiara Bonini, Monica Casucci, Beatrice Greco, Camilla Bove, Silvia Arcangeli, Laura Falcone, Rita El Khoury, Anna De Lucia

“…Background To date, T cells redirected with CD19-specific chimeric antigen receptors (CAR) have gained impressive success in B-cell malignancies. …”
Get full text